CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Description

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Conditions

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Condition
Lymphoma, Non-Hodgkin
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233

Gilbert

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States, 85234

Scottsdale

HonorHealth, Scottsdale, Arizona, United States, 85258

Tucson

University of Arizona Cancer Center, Tucson, Arizona, United States, 85724

Little Rock

University of Arkansas, Little Rock, Arkansas, United States, 72205

La Jolla

University of California San Diego Moores Cancer Center, La Jolla, California, United States, 92073

Los Angeles

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90089

Orange

Chao Family Comprehensive Cancer Center/University of California Irvine, Orange, California, United States, 92868

Orlando

Advent Health, Orlando, Florida, United States, 32803

Atlanta

Bone and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States, 30342

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age greater than or equal to 18 at the time of enrollment
  • * Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
  • * Eastern Cooperative Oncology Group performance status 0 or 1
  • * Adequate hematologic, renal, liver, cardiac and pulmonary organ function
  • * Prior therapy with an anti-CD19 targeting agent
  • * Active or chronic graft versus host disease requiring therapy
  • * Prior allogeneic stem cell transplantation
  • * Central nervous system (CNS) lymphoma, prior CNS malignancy
  • * Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
  • * Primary immunodeficiency
  • * Current or expected need for systemic corticosteroid therapy
  • * Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
  • * Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
  • * Unwillingness to follow extended safety monitoring

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Caribou Biosciences, Inc.,

Study Record Dates

2025-09